SOLNA, Sweden--(BUSINESS WIRE)--Regulatory News:
Aerocrine AB (STO:AEROB) announced today that its handheld airway inflammation monitor, NIOX MINO®, has been registered for marketing and sale in China.
Aerocrine’s method of measuring airway inflammation, using exhaled nitric oxide (NO) tests, has also been incorporated into China’s national guidelines for asthma management. Tests for airway inflammation have received a reimbursement code.
